Drug Profile
Research programme: anti-emesis therapeutics - Paradigm Therapeutics
Alternative Names: SI-162Latest Information Update: 12 Feb 2008
Price :
$50
*
At a glance
- Originator Paradigm Therapeutics
- Developer Takeda Cambridge
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Nausea and vomiting
Most Recent Events
- 27 Apr 2007 No development reported - Preclinical for Emesis in United Kingdom (unspecified route)
- 10 Jan 2005 Amedis Pharmaceuticals has been acquired and merged into Paradigm Therapeutics
- 24 Jun 2004 SI 162 is available for licensing (http://www.amedis-pharma.com)